Form 4: Ionis Pharma Exec Sells Shares After Option Exercise

Ionis Pharmaceuticals' EVP, Chief Human Resources Officer, Shannon L. Devers, exercised stock options and subsequently sold a portion of common stock.

Summary

• Shannon L. Devers, EVP, Chief Human Resources Officer of Ionis Pharmaceuticals Inc. (IONS), reported transactions on September 3, 2025.
• Exercised 2,234 non-qualified stock options at an exercise price of $37.58 per share.
• Exercised an additional 928 non-qualified stock options at an exercise price of $32.60 per share.
• Sold 3,162 shares of common stock at a weighted average price of $61.0192 per share, with individual transaction prices ranging from $61.0075 to $61.045.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 3, 2024.
• Following these transactions, Devers directly owns 15,009 shares of common stock.
• Devers also beneficially owns 13,440 and 13,083 non-qualified stock options, totaling 26,523 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine insider transaction involving the exercise of stock options and subsequent sale of shares, often for personal financial planning or diversification, especially when executed under a Rule 10b5-1 plan. It does not inherently signal strong positive or negative company performance.

Positives

• The exercise of stock options indicates that the executive is realizing value from previously granted equity, suggesting the options were in-the-money.
• The sale price of $61.0192 is significantly higher than the exercise prices of $37.58 and $32.60, indicating a substantial gain for the executive.

Negatives

• Insider selling, even under a pre-arranged plan, can sometimes be interpreted by the market as a move to diversify or a lack of confidence, though it is often for personal financial planning.

Future Outlook

This Form 4 filing details past transactions and does not contain forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider stock transactions for a specific company executive and does not provide broader industry trend information.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock transactions, which can influence investor sentiment regarding insider confidence.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Options, Shannon L. Devers, Equity Sales, Rule 10b5-1